TMCnet News

Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015 - Research and Markets
[February 04, 2016]

Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015 - Research and Markets


Research and Markets (http://www.researchandmarkets.com/research/8d3p3f/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Chronic Lymphocytic Leukemia (CLL) Overview
  3. Therapeutics Development
  4. Pipline Products for Chronic Lymphocytic Leukemia (CLL) - Overview
  5. Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis
  6. Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies
  7. Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes
  8. Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies
  13. Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes
  14. Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development (Partial List)


  • 4SC AG
  • AbbVie Inc.
  • Acetylon Pharmaceuticals, Inc.
  • Altor BioScience Corporation
  • Amgen Inc.
  • Aprogen, Inc.
  • Arno Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • BeiGene(Beijing) Co.,Ltd
  • Bellicum Pharmaceuticals, Inc.
  • Biogen, Inc.
  • BioInvent International AB
  • Bionovis SA
  • Biothera, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellectis S.A.
  • Cellular Biomedicine Group, Inc.
  • Coherus BioSciences, Inc.
  • CTI (News - Alert) BioPharma Corp.
  • Cyclacel Pharmaceuticals, Inc.
  • Eli Lilly and Company
  • Emergent BioSolutions Inc.
  • Epirus Biopharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech, Inc.
  • Genor BioPharma Co., Ltd.
  • Gilead Sciences, Inc.
  • Grupo Ferrer Internacional, S.A.
  • Hospira, Inc.
  • Hutchison MediPharma Limited

For more information visit http://www.researchandmarkets.com/research/8d3p3f/chronic



[ Back To TMCnet.com's Homepage ]